Maxcyte, INC

MaxCyte, Inc. announced that its stockholders approved the election of Class II Directors and ratified the selection of CohnReznick LLP as its independent auditor at the 2026 Annual Meeting.

MaxCyte, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, closing the matter of its delisting concerns.

MaxCyte announced its first quarter 2026 financial results, reporting a 7% decrease in total revenue to $9.7 million, while reiterating its full-year revenue guidance and authorizing a $10 million share repurchase program.

MaxCyte, Inc. announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026, succeeding Douglas Swirsky.

MaxCyte announced its fourth quarter and full year 2025 financial results, reporting revenue at the top of its preliminary range but providing lower revenue guidance for 2026 due to customer headwinds.

MaxCyte, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

MaxCyte reports a 7% year-over-year revenue decrease for Q1 2026, driven by lower core revenue, though SPL milestones and royalties saw a significant increase.

MaxCyte, Inc. reported a significant increase in net loss and a decrease in total revenue for the third quarter and first nine months of 2025, alongside a major workforce reduction and CFO transition.

MaxCyte, Inc. reported an 18% decline in total revenue for Q2 2025, primarily due to a significant decrease in non-core program-related revenue, despite an 8% increase in core revenue.

MaxCyte's Q1 2025 results show a slight revenue decrease and a net loss, but the company highlights the acquisition of SeQure Dx and a new SPL agreement.

MaxCyte's third quarter results show a 17% increase in revenue year-over-year, driven by disposables and program-related revenue, while the company continues to invest in growth and development.

MaxCyte's second quarter 2024 results show a revenue increase driven by strategic platform licenses, despite a decrease in core revenue.

MaxCyte reported a wider net loss of $44.6 million in 2025, driven by decreased core revenue and a workforce reduction, despite strategic acquisition and platform expansion.

MaxCyte's 10-K filing summarizes the company's financial performance for 2024, highlighting its cell engineering technology and strategic platform license agreements.

MaxCyte's 2023 annual report details financial performance, strategic partnerships, and future growth plans in the cell engineering and life sciences sector.

MaxCyte CFO Parmeet Ahuja was granted 187,500 restricted stock units as part of an equity compensation arrangement.

Maxcyte, Inc. reports that Chief Financial Officer Parmeet Ahuja acquired 375,000 employee stock options.

MAXCYTE, INC. President and CEO, Maher Masoud, acquired 300,000 restricted stock units and 600,000 employee stock options, aligning executive incentives with long-term company performance.

MaxCyte's Chief Financial Officer, Douglas J. Swirsky, sold 10,142 shares of common stock to cover tax withholding obligations related to RSU vesting.

MAXCYTE Director Rekha Hemrajani sold 10,684 shares of common stock for a weighted average price of $2.0945 per share, pursuant to a pre-arranged 10b5-1 trading plan.

MAXCYTE's Chief Financial Officer, Douglas J Swirsky, acquired 50,000 shares of common stock at $1.29 per share.

MaxCyte, Inc. is soliciting stockholder votes for its 2025 Annual Meeting, proposing the election of three Class I directors, an increase in its equity incentive plan shares, and the cancellation of its AIM trading admission.

MaxCyte is asking stockholders to approve an amendment to its equity incentive plan and to delist from the AIM market of the London Stock Exchange.

MaxCyte is asking stockholders to approve an amendment to its 2022 Equity Incentive Plan to increase the number of shares available for issuance by 2,300,000 at the Annual Meeting on June 11, 2024.

River Global Investors LLP reports a shift in beneficial ownership of Maxcyte, Inc. equity due to an acquisition of its parent entity, with a portion of voting rights transferring to Liontrust Investment Partners.

River Global Investors LLP has reported a beneficial ownership of 6,529,027 shares, representing 6.1% of the outstanding equity in Maxcyte, Inc., acquired through open-market transactions.

River Global Investors LLP has disclosed a 5.1568% beneficial ownership stake in MAXCYTE, INC., acquiring over 5.4 million equity shares.

Mirabella Financial Services LLP has filed a Schedule 13G, reporting zero shares beneficially owned in Maxcyte, Inc. as of March 31, 2026, due to no longer acting as Investment Manager for Blue Riband Fund LP.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in MaxCyte Inc. following an internal corporate realignment.

Cadian Capital Management and its affiliates reported a 3.5% beneficial ownership stake in MaxCyte, Inc. as of December 31, 2025.

Capricorn Fund Managers Ltd has reported a 7.7% beneficial ownership stake in MAXCYTE, INC. common stock.

BlackRock, Inc. has disclosed an increased beneficial ownership of 6.6% in MAXCYTE, INC.'s common stock, totaling 6,997,197 shares.

Cadian Capital Management and affiliates report a 7.7% beneficial ownership stake in MaxCyte, Inc., holding over 8.2 million shares.